<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01645449</url>
  </required_header>
  <id_info>
    <org_study_id>10-VIN-095</org_study_id>
    <nct_id>NCT01645449</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Atorvastatin Calcium Tablets, 80 mg of Dr. Reddy's Under Fasting Conditions</brief_title>
  <official_title>An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-way Crossover Oral BE Study of Atorvastatin Ca 80 mg Tablets of Dr. Reddy's and Lipitor 80 mg Tablets of Pfizer in Healthy Adult, Human Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare and evaluate the single-dose oral bioavailability and
      to monitor the safety of subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open label, balanced, randomized, two-treatment, two-period, two-way crossover oral
      bioequivalence' study of Atorvastatin Calcium 80 mg Tablets of Dr. Reddy's and Lipitor 80 mg
      Tablets of Pfizer Ireland Pharmaceuticals in healthy adult, human subjects under fasting
      conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under curve (AUC)</measure>
    <time_frame>Pre-dose at 0.00 hour and post-dose at 0.167, 0.333, 0.50, 0.667, 0.833, 1.00, 1.25, 1.50, 1.75, 2.00, 2.25, 2.50, 2.75, 3.00, 3.50, 4.00,6.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00, 48.00 and 72.00 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Atorvastatin Calcium Tablets, 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atorvastatin Calcium Tablets, 80 mg of Dr. Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lipitor 80 mg Tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lipitor 80 mg Tablets of Pfizer Ireland Pharmaceuticals</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin Calcium Tablets, 80 mg</intervention_name>
    <description>Atorvastatin Calcium Tablets, 80 of Dr. Reddy's Laboratories Limited</description>
    <arm_group_label>Atorvastatin Calcium Tablets, 80 mg</arm_group_label>
    <arm_group_label>Lipitor 80 mg Tablets</arm_group_label>
    <other_name>Lipitor 80 mg Tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female subjects aged 18 - 55 (including) years old.

          2. Subjects' weight within normal range according to normal values for Body Mass Index (1
             8.0 to 30.0 kg/m2) with minimum of 50 kg weight.

          3. Subjects with normal health as determined by personal medical history, clinical
             examination and laboratory examinations within clinically acceptable range.

          4. Subjects having normal 12-lead electrocardiogram (ECG).

          5. systolic blood pressure between 90 mmHg to 145 mmHg (age 18 to 45 years) or 90 mmHg to
             160 mmHg (above 45 years). Diastolic blood pressure between 50 mrnHg to 90 rnmHg.
             Pulse rate between 45 bpm and 100 bpm.

          6. Subjects having negative urine screen for drugs of abuse (including amphetamines,
             barbiturates, benzodiazepines, cannabinoids, cocaine, and morphine).

          7. Subjects having negative alcohol breath test.

          8. Women who are of childbearing potential must be using acceptable methods of birth
             control for 4 weeks prior to, during and 4 weeks after the last dose of trial
             medication and should be informed of the potential risks associated with becoming
             pregnant while enrolled within a clinical research trial. Accepted forms of
             contraception are: i.e. implants, injectables, hormonal intrauterine device, combined
             oral contraceptives, sexual abstinence and vasectomised sexual partner throughout the
             trial. Female volunteers who are post-menopausal, hysterectomised or surgically
             sterile may be enrolled.

          9. Subjects willing to adhere to the protocol requirements and to provide written
             informed consent.

        Exclusion Criteria:

        The subjects were excluded from the study, if they met any of the following criteria:

          1. Hypersensitivity to the test, or reference drug, or all other used ingredients, or
             related class of drugs.

          2. History or presence of significant cardiovascular, pulmonary, hepatic, renal,
             gastrointestinal, endocrine, immunological, dermatological,neurological or psychiatric
             disease or disorder.

          3. Individual or farniliy case medical history of any myopathy.

          4. Any treatment which could bring about induction or inhibition of hepatic microsomal
             enzyme system within 1 month before first dosing in Period 1.

          5. Medical history of muscular toxic reactions during treatment with statins of fibrates.

          6. Use of any prescribed or OTC medication or herbal supplements within 14 days or within
             5 times the half-life of the respective active substance (whatever is longer), before
             first dosing in Period 1 (excluding contraceptives on women).

          7. History or presence of significant alcoholism or drug abuse in the past one year.
             Alcoholism is defined as consumption of more than 50g of ethanol per day (12.5 cL
             glass of 10째 [l0%]] wine = 12 g; 4 cL of aperitif, 42째 [42 %] whiskey = 17 g; 25 cL
             glass of 3째 [3%] beer = 7.5 g; 25 cL glass of 6째 [6%] beer = 15 g.

          8. History or presence of significant smoking (more than 10 cigarettes/day).

          9. History or presence of asthma, urticaria or other significant allergic reactions.

         10. History or presence of significant gastric andlor duodenal ulceration.

         11. History or presence of significant thyroid disease, adrenal dysfunction, organic
             intracranial lesion such as pituitary tumor.

         12. History or presence of cancer.

         13. Difficulty with donating blood.

         14. Difficulty in swallowing solids like tablets or capsules.

         15. Major illness during 3 months before first dosing in Period 1.

         16. Participation in a drug research study within the past 1 month before first dosing in
             Period 1.

         17. Donation of blood in the past 2 months before first dosing in Period 1.

         18. Consumption of grapefruit juice, xanthine-containing products or alcohol for within 48
             hours prior to dosing.

         19. Positive screening test for any one or more: HIV, Hepatitis B and Hepatitis C.

         20. History or presence of significant easy bruising or bleeding.

         21. History or presence of significant recent trauma.

         22. Pregnancy or breast-feeding (for female subjects).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. med. Margarete Muller</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nuvisan Pharma Services GmbH &amp; Co. KG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nuvisan Pharma Services GmbH &amp; Co. KG</name>
      <address>
        <city>Neu-Ulm</city>
        <zip>89231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2012</study_first_submitted>
  <study_first_submitted_qc>July 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2012</study_first_posted>
  <last_update_submitted>July 19, 2012</last_update_submitted>
  <last_update_submitted_qc>July 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Atorvastatin calcium</keyword>
  <keyword>crossover</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Atorvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

